Nectar Lifesciences News
- Market cap
- ₹201 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹7.44 – ₹13.95
The latest update on Nectar Lifesciences is "Nectar Lifesciences Limited Reports Operational Performance & Quarterly Growth Update" (BSE Corporate Announcement), published 9 October 2026. This page lists 4 recent headlines and exchange announcements, 2 of them filed on BSE. Nectar Lifesciences' next board meeting for results is scheduled for 3 November 2026.
Latest Nectar Lifesciences news and announcements
Next results board meeting: 3 November 2026.
- Nectar Lifesciences Limited Reports Operational Performance & Quarterly Growth Update
- Market Activity: Nectar Lifesciences Limited Shares See Strong Institutional Volume
- Nectar Lifesciences Limited Board Compliances & Mandatory Disclosure Filings Submitted
- Analyst Review: Key Valuation Overview & Target Projection for Nectar Lifesciences Limited
Source: Publisher headlines and announcements filed on BSE, linked to their original sources. Data as of 9 October 2026. How this data is compiled.
Nectar Lifesciences news & announcements — frequently asked questions
What is the latest news on Nectar Lifesciences?
The most recent item is "Nectar Lifesciences Limited Reports Operational Performance & Quarterly Growth Update" from BSE Corporate Announcement on 9 October 2026. The full list above links to each original source.
When are Nectar Lifesciences' next results?
Nectar Lifesciences has announced a board meeting on 3 November 2026 to consider its financial results, according to its filing on BSE.
Where do these Nectar Lifesciences headlines come from?
Headlines link to the original publisher, and exchange announcements link to the filing on BSE. ATS lists them by date and does not rewrite or summarise them.
Same Data For Peers
Trade Nectar Lifesciences With ATS
Track NECLIFE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.